Phase 3 Efficacy and Safety Study of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients With Her2-positive Early Breast Cancer

Trial Profile

Phase 3 Efficacy and Safety Study of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients With Her2-positive Early Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Celltrion
  • Most Recent Events

    • 04 Jun 2017 Results from this trial published in a Celltrion Media Release.
    • 02 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Jun 2017 Results assessing similarity of CT-P6 and trastuzumab in efficacy and safety for HER2+ EBC, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top